Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis

M. Rudwaleit, J. T. Rosenbaum, R. Landewé, H. Marzo-Ortega, J. Sieper, D. Van Der Heijde, O. Davies, H. Bartz, B. Hoepken, T. Nurminen, A. Deodhar

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Objective Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine and sacroiliac joints and can also affect extraarticular sites, with the most common manifestation being uveitis. Here we report the incidence of uveitis flares in axial SpA patients from the RAPID-axSpA trial, including ankylosing spondylitis (AS) and nonradiographic (nr) axial SpA. Methods The RAPID-axSpA (NCT01087762) trial is double-blind and placebo-controlled to week 24, dose-blind to week 48, and open-label to week 204. Patients were randomized to certolizumab pegol (CZP) or placebo. Placebo patients entering the dose-blind phase were re-randomized to CZP. Uveitis events were recorded on extraarticular manifestation or adverse event forms. Events were analyzed in patients with/without history of uveitis, and rates reported per 100 patient-years. Results At baseline, 38 of 218 CZP-randomized patients (17.4%) and 31 of 107 placebo-randomized patients (29.0%) had past uveitis history. During the 24-week double-blind phase, the rate of uveitis flares was lower in CZP (3.0 [95% confidence interval (95% CI) 0.6-8.8] per 100 patient-years) than in placebo (10.3 [95% CI 2.8-26.3] per 100 patient-years). All cases observed during the 24-week double-blind phase were in patients with a history of uveitis; in these patients, rates were similarly lower for CZP (17.1 [95% CI 3.5-50.1] per 100 patient-years) than placebo (38.5 [95% CI 10.5-98.5] per 100 patient-years). Rates of uveitis flares remained low up to week 96 (4.9 [95% CI 3.2-7.4] per 100 patient-years) and were similar between AS (4.4 [95% CI 2.3-7.7] per 100 patient-years) and nr-axial SpA (5.6 [95% CI 2.9-9.8] per 100 patient-years). Conclusion The rate of uveitis flares was lower for axial SpA patients treated with CZP than placebo during the randomized controlled phase. Incidence of uveitis flares remained low to week 96 and was comparable to rates reported for AS patients receiving other anti-tumor necrosis factor antibodies.

Original languageEnglish (US)
Pages (from-to)838-844
Number of pages7
JournalArthritis Care and Research
Volume68
Issue number6
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis'. Together they form a unique fingerprint.

  • Cite this

    Rudwaleit, M., Rosenbaum, J. T., Landewé, R., Marzo-Ortega, H., Sieper, J., Van Der Heijde, D., Davies, O., Bartz, H., Hoepken, B., Nurminen, T., & Deodhar, A. (2016). Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis. Arthritis Care and Research, 68(6), 838-844. https://doi.org/10.1002/acr.22848